Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein was independently associated with ileal CD but non-signficant in a multivariate model.
|
31769537 |
2020 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this real-life prospective cohort utilizing dose optimization, thiopurines were safe and effective in 21% of CD and 27% of UC patients, including normalization of CRP and ESR.
|
31764416 |
2020 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Crohn's disease activity index (CDAI), Mayo score, C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) were measured.
|
31749597 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fift y-three adult patients with proven CD underwent magnetic resonance enterocolonography (MR-EC), colonoscopy, and clinical activity assessment, including CRP.
|
31737782 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum DKK-1 level was correlated with levels of ESR (r=0.527, P=0.025), CRP (r=0.502, P=0.034), albumin (r=0.363, P=0.021) and PCDAI (r =0.462, P=0.054) in Crohn disease.
|
31729323 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The variables used were Crohn's disease activity index (CDAI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
|
31689999 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Before treatment and 10 weeks later we collected: clinical activity [Harvey Bradshaw Index (HBI) and Crohn's-Disease-Activity-Index (CDAI)], serum C-reactive protein (CRP) and fecal calprotectin, and BSFS (1-7) and a 100-mm VAS based on a 7-day diary.
|
31651651 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the characteristics of disagreement, and analyzed the relationships with the Crohn's Disease Activity Index (CDAI) and C-reactive protein.
|
31541367 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
FC value had significant positive correlation with CRP, HBI and leukocyte values when measured at similar timepoints.<b>Conclusions:</b> Elevated level of FC approximately 1 year after the initiation of biological therapy was associated with an increased risk of either surgical procedures, corticosteroid initiation, treatment failure or dose increase (i.e. composite outcome) in patients with CD.
|
31532265 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Following infliximab, FC and CRP declined (<i>p</i> < .0001) along with HBi for CD and pMCS for UC.
|
31499013 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> In suspected CD, low serum iron and elevated CRP had a statistically significant association with CD diagnosis, being helpful to identify patients with higher CD probability before SBCE.
|
31378118 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the interpretation of CRP and FC in patients with CD within specific clinical contexts and according to assay performance characteristics.
|
31327404 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions:</b> Baseline CRP level and CRP reduction rate might be clinical predictors for PNR or LOR to anti-TNF in patients with CD, and could guide proper therapeutic interventions in patients with CD.
|
31303093 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We performed a nonblinded, randomized controlled trial of 78 children with CD (6-18 years old; 29% female; mean age, 14.3 ± 2.6 years) who had not received prior treatment with a biologic agent but had responded to adalimumab induction therapy, under scheduled monitoring of clinical and biologic measures (based on clinical factors and levels of C-reactive protein and fecal calprotectin), at pediatric gastroenterology units in Israel from July 2015 through December 2018.
|
31194979 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined monitoring of CDAI, CRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with CD.
|
31148906 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum 25(OH)D<sub>3</sub> was inversely correlated with faecal calprotectin (FC) for CD and UC but was only correlated with C-reactive protein (CRP) for UC patients.
|
31083541 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with CD with above-average free thiols had significantly lower CRP levels (median 1.4 [interquartile range] [0.4; 2.6] vs. 3.6 [0.6; 7.0] mg/L; <i>P</i> < 0.05) and BMI (23.6 ± 4.8 vs. 27.1 ± 5.2 kg/m<sup>2</sup>; <i>P</i> < 0.05).
|
31080419 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The clinical response to treatment was assessed using the Crohn's disease activity index and C-reactive protein (CRP) values.
|
30874986 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRP and Fcal may be accurate in prediction of MH of CD when MH is evaluated throughout the entire intestine including the small bowel.
|
30873890 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging evidence indicates that CRP and FC are valuable adjuncts for the management of CD in specific circumstances described in this review.
|
30791776 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inclusion criteria included: a diagnosis of ulcerative colitis or Crohn's disease with objective evidence of active inflammation at baseline (Harvey-Bradshaw Index[HBI] ≥5/Partial Mayo ≥2 plus C-reactive protein [CRP] >5 mg/L or faecal calprotectin ≥250 µg/g or inflammation on endoscopy/magnetic resonance imaging [MRI]); completion of induction; and at least one clinical follow-up by 12 months.
|
30768123 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, PentraSorb CRP provides a novel, specific, and efficient CRP-binding resin that could be used in apheresis therapy for patients suffering from inflammatory diseases such as AMI, stroke, acute pancreatitis, and Crohn's disease.
|
30697961 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, lncRNA ANRIL expression was negatively associated with Crohn's disease activity index (P = 0.002), C-reactive protein (P < 0.001) and erythrocyte sedimentation rate (P = 0.001), and associated with tumor necrosis factor-α (P < 0.001), IL-17 (P < 0.001) and interferon gamma messenger RNA levels (P = 0.004) but positively associated with IL-10 messenger RNA level (P = 0.002).
|
30665494 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, CRP at baseline was negatively correlated with p-VDZ at week 14 in CD but not in UC patients.
|
30650312 |
2019 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Disease behavior/presence of steroid exposure and elevated CRP were associated with hospitalization among CD and UC patients who visited the ED, respectively.
|
30650133 |
2019 |